NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
Ford explains that Mabvax is attractive due to multiple potential upcoming catalysts. According to the report, "This is an exciting time for MabVax (OTCQB:MBVX), shareholders because the company's share price could rise from $2 to over $5 in the next few weeks based on MabVax's extreme level of undervaluation and 2 imminent catalysts."
Today Mabvax is trading on strong volume based on the continued investment by Dr. Phillip Frost and Opko (NYSE: OPK), which has the shares trading slightly higher.
The report can be found at http://seekingalpha.com/author/john-h-ford/instablog
Some of the highlights from Ford's research:
- MabVax is completely undiscovered by Wall Street and would be undervalued even if the share price doubled.
- Dr. Phillip Frost and Opko (NYSE OPK) just invested in MabVax and given Dr. Frost's track record, MabVax could be another home run trade.
- In neuroblastoma trials MabVax demonstrated its drug is almost twice as effective as the standard of care.
- The Cancer Immunotherapy Index has risen almost 50% this year and MabVax is a major contender in that sector.
About Market Exclusive
Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive
